{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.3.', 'Primary and Secondary Efficacy Measures and Time Points', 'A description of the efficacy measures is provided in Section 6.', '3.3.1.', 'Primary Efficacy Measure and Time Points', 'YGTSS (to calculate TTS): Screening; baseline; and weeks 2, 4, 6, 9, 12, and 13.', '3.3.2.', 'Key Secondary Efficacy Measures and Time Points', '1.', 'TS-CGI: baseline and weeks 2, 4, 6, 9, 12, and 13', '2.', 'TS-PGII: baseline and weeks 2, 4, 6, 9, 12, and 13', '3.', 'C&A-GTS-QOL ADL subscale: baseline, week 6, and week 12', '3.3.3.', 'Exploratory Measures and Time Points', '3.4.', 'Safety Measures and Time Points', 'adverse events and concomitant medications: from the signing of the informed', \"consent/assent, depending on the child's age, as appropriate, through follow-up,\", 'inclusive of all visits and telephone contacts', 'physical examination: screening and week 12', 'neurological examination: screening and week 12', 'vital signs: screening; baseline; and weeks 2, 4, 6, 9, 12, and 13', 'Note: orthostatic blood pressure (BP) and pulse at baseline and weeks 4 and 12', 'MINI Kid: screening', '46']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', \"Children's C-SSRS\", '- Baseline/screening scale: screening', '-', 'Since Last Visit [SLV] scale: baseline and weeks 2, 4, 6, 9, 12, and 13', 'CDI-2 (Parent and Self-Report versions): screening; baseline; and weeks 2, 4, 6, 9,', '12, and 13', '12-lead ECG: screening; baseline; and weeks 4, 6, and 12', 'clinical laboratory tests (serum chemistry, hematology, and urinalysis): screening and', 'week 12', 'pregnancy testing: screening, baseline, and weeks 4 and', '12', 'drug screen: screening and week 12', 'A description of the safety measures is provided in Section 7.', '3.5.', 'Pharmacokinetic Measures and Time Points', 'Blood samples will be obtained for the measurement of plasma concentrations of TEV-50717', '(deutetrabenazine), -HTBZ, \u00df-HTBZ, and other metabolites, as needed. Blood sampling for', 'pharmacokinetic analysis will be performed at the week 12 visit. Two samples will be collected.', 'The first sample will be collected upon arrival at the clinic. The second sample will be collected', '2 to 3 hours after the first pharmacokinetic sample collection. The time between samples should', 'be maximized in order to provide the most useful information.', 'A description of the pharmacokinetic measures is provided in Section 8.', '3.6.', 'Randomization and Blinding', 'This is a randomized, double-blind, placebo-controlled study. Patients will be randomly assigned', 'to receive treatment with TEV-50717 or matching placebo in a 1:1 ratio stratified by age at', 'baseline (6 to 11 years, 12 to 16 years). Patients and investigators will remain blinded to', 'treatment assignment during the study.', 'Patients will be centrally randomly assigned to the treatment groups by means of a', 'computer-generated randomization list after confirmation of all eligibility criteria. The creation', 'of the randomization list will be under the responsibility and oversight of Syneos Health.', \"In addition, the sponsor's clinical personnel and all vendors (with exception of the IRT vendor\", 'and the bioanalytical sample analysis vendor) involved in the study will be blinded to the IMP', 'identity until the database is locked for analysis and the treatment assignment revealed. After', 'unblinding of this study, the study site may remain blinded to patient treatment assignments until', 'completion of the safety extension study TV50717-CNS-30047.', 'The randomization list and treatment will be assigned to the relevant treatment groups through a', 'qualified service provider (ie, via IRT). The generation of the medication list and management of', 'the IRT system will be done by a qualified service provider under the oversight of Nuvelution TS', 'Pharma.', '47']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The staff member at the investigational center who will dispense the IMP will not know the', 'treatment given to each patient.', '3.7.', 'Maintenance of Randomization and Blinding', '3.7.1.', 'Randomization', 'Patient randomization codes will be maintained in a secure location within Syneos Health,', 'Biometrics. At the time of analysis, when treatment codes are needed, the Syneos Health', 'statistician assigned to the study will make a request to unblind and will receive the unblinded', 'codes.', '3.7.2.', 'Blinding/Unblinding', 'Pharmacokinetic data may be assessed during the study. For patients who have pharmacokinetic', 'sample bioanalysis and/or data analysis conducted, the individuals responsible for sample', 'bioanalysis and other responsible personnel will know who received IMP and who received', 'placebo during the study (of those patients only). Personnel responsible for bioanalysis will be', 'provided with the randomization code in order to facilitate the analysis. However, the personnel', 'responsible for bioanalysis and pharmacokinetic data analysis will not have access to clinical', 'safety and efficacy data, will not have any interaction with study personnel, and will provide', 'concentration data to other personnel in a manner that will not identify individual patients (ie, a', \"dummy patient identifier will be linked to an individual patient's concentration data).\", 'For information about personnel who may be aware of treatment assignments, see Section 3.6.', 'These individuals will not be involved in conduct of any study procedures or assessment of any', 'adverse events.', 'In case of a serious adverse event or pregnancy, or in cases when knowledge of the IMP', \"assignment is needed to make treatment decisions, the investigator may unblind the patient's\", 'IMP assignment as deemed necessary, mainly in emergency situations. Individual treatment', 'codes, indicating the treatment randomization for each randomized patient, will be available to', 'the investigator(s) and/or pharmacist(s) at the study center via the IRT system. If possible, the', 'sponsor should be notified of the event prior to breaking of the code. If this is not possible, the', \"sponsor should be notified immediately afterwards, and the patient's drug code assignment\", 'should not be revealed. Breaking of the treatment code can always be performed by the site', 'without prior approval by the sponsor.', 'When a blind is broken, the patient will be withdrawn from the study, and the event will be', 'recorded onto the case report form (CRF). However, if a patient is unblinded by mistake, the', 'investigator should discuss with the medical monitor whether or not the patient should be', 'withdrawn. The circumstances leading to the breaking of the code should be fully documented in', \"the investigator's study files and in the patient's source documentation. Treatment assignment\", 'should not be recorded in any study documents or source document.', 'In blinded studies, for adverse events that are defined as: suspected unexpected serious adverse', 'reactions (SUSARs) (ie, reasonable possibility; see Section 7.1.4), Global Patient Safety and', 'Pharmacovigilance (GPSP) may independently request that the treatment code be revealed (on a', 'case-by-case basis) to comply with regulatory requirements. The report will be provided in an', '48']\n\n###\n\n", "completion": "END"}